SIFI Merges with Faes Farma to Enhance Global Ophthalmic Presence and Improve Access to Treatments

SIFI and Faes Farma: A New Chapter in Ophthalmology

In a significant move in the pharmaceutical landscape, SIFI, a leading ophthalmic company, has announced its merger with Faes Farma, a prominent European pharmaceutical firm. This union is aimed at transforming the way ophthalmic treatments are developed and distributed worldwide. The agreement, confirmed on June 10, 2025, marks a pivotal step in SIFI's long-standing mission to enhance global access to innovative eye care solutions.

Strategic Significance of the Merger

The merger is expected to create considerable commercial synergies. Faes Farma's extensive reach in complementary markets and its recent acquisition of Laboratorios Edol will provide a strengthened base for SIFI's product portfolio. Through this integration, SIFI can leverage Faes Farma's established market presence in various regions, including Italy, France, Romania, and Turkey, while also enhancing its footprint in the Iberian Peninsula, Mexico, and Latin America.

According to Fabrizio Chines, CEO of SIFI, this merger will allow the combined entity to accelerate growth and enhance value for all stakeholders by expanding the global reach of crucial ophthalmic medicine. Underlining the quality and innovation synonymous with the SIFI brand, Chines emphasized the goal of advancing ophthalmology and improving patient outcomes through collaborative efforts.

Expanding Product Development and Market Access

With this merger, SIFI is poised to further develop its key product, Akantior, a pioneering therapy for the treatment of Acanthamoeba Keratitis. Akantior is currently approved in Europe and the UK, marking it as the world's first specific treatment for this rare infection affecting the cornea. The product, launched in Germany in October 2024, is anticipated to gain further approvals and market access across other European nations and the United States, where it is undergoing pre-registration with the FDA.

The merger will also open new avenues for the development of other orphan indications, such as polihexanide for fungal keratitis, a promising field following encouraging preclinical results. This expansion into new therapeutic areas reflects SIFI's commitment to addressing unmet medical needs and diversifying its portfolio under the enhanced operational efficiencies expected from the merger.

Commitment to Quality and Innovation

SIFI will continue to operate its two cutting-edge facilities in Aci S. Antonio, Italy, focusing on the production of ophthalmic drugs and intraocular lenses. This infrastructure is supported by long-term manufacturing contracts that promise recurrent revenue. SIFI’s state-of-the-art production capabilities will help optimize the combined group's industrial capacity, ensuring operational excellence and cost efficiency.

Eduardo Recoder de la Cuadra, CEO of Faes Farma, reaffirmed the complementary nature of both companies, emphasizing the shared values and cultures that would facilitate a smooth integration process. He noted that the merger strengthens Faes Farma’s position in the ophthalmology sector, which presents significant growth potential, and aligns with their commitment to develop a more extensive, innovative product range for professionals and patients alike.

Conclusion: A Promising Future Ahead

The estimated valuation of this transaction marks a milestone for SIFI, involving a multiple of the EBITDA for 2024, with additional performance-linked price adjustments. The completion of this merger is expected in the third quarter of 2025, subject to regulatory approvals and other customary conditions. As the healthcare landscape continues to evolve, the integration of SIFI and Faes Farma heralds a new era of opportunity in ophthalmic care, aimed at improving patient outcomes globally.

For more information about SIFI and its innovative ophthalmology solutions, visit SIFI Group and learn about Faes Farma’s commitment to healthcare advancements at Faes Farma.

Together, SIFI and Faes Farma are set to redefine ophthalmic treatment accessibility, ensuring that high-quality eye care solutions are available to those who need them the most.